Skip to content

A study to find out if a new blood test (microRNA) can be used to monitor people after surgery for seminoma or dysgerminoma cancer

A phase II/III trial evaluating use of circulating serum miRNA as part of active surveillance for patients with stage I seminoma and dysgerminoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN92524070
Enrollment
818
Registered
2026-01-14
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seminoma and dysgerminoma Cancer

Interventions

OTIS-S will include patients with stage I seminoma or dysgerminoma and will use a seamless, phased approach to evaluation. In part A (single-arm), 260 patients will undergo regular miRNA testing along

Sponsors

Institute of Cancer Research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed testicular pure seminoma* or extra-cranial dysgerminoma 2. Primary cancer managed by orchiectomy or complete surgical removal of dysgerminoma (trial entry is permitted within 8 weeks following surgery, up to a maximum of 10 weeks under exceptional circumstances.) 3. Stage I based on CT or MRI abdomen and pelvis and CT chest. For participants under the age of 19, pelvic ultrasound (US) may be used at physician’s discretion where MRI is not possible or where US is used routinely at site. 4. Normal post-operative tumour markers as follows (may have been raised pre-operatively and immediately post-operatively, but have returned to normal range): a.AFP 10 and < = 25 ng/ml and confirmed as not rising on three successive tests may be accepted as eligible after discussion with Chief Investigator or delegate] b.ß-HCG< = 4 IU/L c.LDH< 1.2 x upper limit of normal 5. No adjuvant therapy planned 6. Participant (or, where the participant is under 16 years old, their parent or guardian) has given written informed consent prior to any study-specific procedures. *Patients with any non-seminomatous elements, including teratoma, are not eligible

Exclusion criteria

Exclusion criteria: 1. Previous contralateral testis tumour within 3 years of trial entry. 2. Previous or concurrent illness or condition which, in the investigator’s opinion, would interfere with participation in the trial 3. Pregnancy (pregnancy can be excluded on the basis of ß-HCG result) 4. Unable/unwilling to comply with trial visit schedule/trial assessments.

Countries

England, Northern Ireland, Scotland, United Kingdom, Wales

Contacts

Public ContactDeborah Gardiner
otis-s-icrctsu@icr.ac.uk+442087224057

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026